$PBH (Prestige Brands Holdings, Inc.)

$PBH {{ '2016-05-12T13:39:42+0000' | timeago}} • Webcast

$PBH said that in FY17, it anticipates core over-the-counter brands will continue to grow faster than the categories in which they compete. The company expects headwinds at retail from industry consolidation and impact on top line results from foreign currency exchange rates. $PBH expects revenue growth of 6.5-8.5% in 1H17 and 5.5-7.5% in 2H17.

$PG {{ '2017-09-22T17:25:15+0000' | timeago}} • Announcement

$PG issued statement in response to the report issued by Glass Lewis. The company reiterated that significant transformation is delivering shareholder value. The Board has done its homework and concluded that Nelson Peltz is Not the right director. $PG urged shareholders to vote "For" all of its directors on the Blue proxy card.

$PG {{ '2017-09-22T17:22:10+0000' | timeago}} • Announcement

$PG issued statement in response to the report issued by Glass Lewis regarding the election of directors to the company's Board at its annual meeting to be held on Oct. 10, 2017. $PG is disappointed that Glass Lewis failed to recognize the significant transformation that the Board and team are implementing for the benefit of all shareholders.

$AGN {{ '2017-09-22T14:30:34+0000' | timeago}} • Announcement

$AGN announced top-line results from new data for the Centaur Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. $AGN is currently enrolling patients in a 2,000 patient phase 3 clinical trial of CVC called the Aurora trial.

$ABT {{ '2017-09-22T12:26:48+0000' | timeago}} • Announcement

$ABT got the FDA nod for magnetic resonance (MR)-conditional labeling for its implantable cardioverter defibrillators (ICD) and associated high voltage leads. The new MR-conditional labeling for the Ellipse ICD allows patients to undergo an MRI scan. Patients implanted with Ellipse device and Durata or Optisure leads can also undergo MRI scans.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

$BMY {{ '2017-09-22T11:37:45+0000' | timeago}} • Announcement

$BMY announced that Japan Ministry of Health, Labor and Welfare approved 'Opdivo.' The nivolumab drug is used in the treatment of patients with unresectable advanced or recurrent gastric cancer progressing after chemotherapy.

$NKTR {{ '2017-09-21T21:21:13+0000' | timeago}} • Announcement

$NKTR appointed Jeff Ajer, EVP and Chief Commercial Officer of BioMarin, as an independent director to Nektar's BoD. Ajer has more than 25 years of biotechnology industry experience within rare disease and specialty medicine.

$CORE {{ '2017-09-21T13:02:10+0000' | timeago}} • Announcement

$CORE, marketers of fresh and broad-line supply solutions to convenience retail industry, has announced that it has renewed its 3-year supply chain agreement with $RAD. Core-Mark is currently providing service to approx 4,500 Rite Aid stores. Finer details of the agreement are under wraps.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

$RAD {{ '2017-09-19T15:31:35+0000' | timeago}} • Announcement

Under the amended and restated asset purchase agreement with $RAD, $WBA does not expect the transaction to have a significant impact to its adjusted EPS in FY17. $WBA also expects to realize annual synergies from the transaction of more than $300MM, which are expected to be fully realized within four years of the initial closing of the transaction.

$WBA {{ '2017-09-19T14:19:18+0000' | timeago}} • Announcement

Drugstore chain $WBA, in its fourth attempt, clinched regulatory approval to buy 1,932 stores, 3 distribution centers and related inventory from $RAD for $4.375Bil. The new deal has 250 fewer stores than the earlier deal & is lower than the previous proposal of $5.18Bil. Store purchases would begin in Oct., with completion expected in spring 2018.

$ABT {{ '2017-09-18T12:47:46+0000' | timeago}} • Announcement

$ABT is extending its previously announced tender offer to purchase all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. for $402 per share of Preferred Stock. The offer is being extended to allow additional time for the consummation of the merger, which is a condition to the completion of the offer.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$ABT {{ '2017-09-14T16:50:10+0000' | timeago}} • Announcement

$ABT BoD declared a quarterly common dividend of $0.265 per share. The dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$CLX {{ '2017-09-13T13:01:19+0000' | timeago}} • Announcement

$CLX said its BoD declared a quarterly dividend of 84 cents per share on the company's common stock. The dividend is payable on Nov. 13, 2017, to stockholders of record on Oct. 25, 2017.

Recent Transcripts

ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
CLX (The Clorox Company)
Thursday, August 3 2017 - 5:30pm
CHD (Church & Dwight Co. Inc.)
Thursday, August 3 2017 - 2:00pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
CL (Colgate-Palmolive Co.)
Friday, July 21 2017 - 3:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm

AlphaGraphics you may like